Founded in 1968, Almac supports drug substance and drug product analytics across all phases, from early phase pre-clinical / clinical development to commercial release.
Over the past 18 months, Almac Sciences and Almac Pharma Services have jointly made this significant investment to expand their existing analytical laboratories, technology and resources to meet ongoing global demand.
Construction of new laboratory space at the company’s global Headquarters in Craigavon considerably increases overall capacity, while additional upgrades and development of existing labs across all sites mean Almac will increase its existing global analytical employee headcount by over 100 in the next 12 months.
Darren Thomas, vice president of analytical operations, Almac Sciences, said: "We have experienced a significant increase in demand for our dedicated analytical solutions and recognise the importance of continually investing, not just in our systems and facilities, but also in our people.
"We are committed to offering a best-in-class service to our global client base and are delighted to continue at pace with significant investment across our UK, EU and US facilities in order to strengthen our competitive position in the marketplace."
Trevor Clarke, vice president of analytical operations, Almac Pharma Services, added: "We are positioned as the partner of choice with significant experience in a wide range of analytical services to meet the varying requirements of our clients’ unique development and commercial programmes.
"This significant investment in innovative technology, skilled talent, and state-of-the-art laboratories underscores our dedication to providing comprehensive analytical solutions for our clients worldwide."
